Despite reporting positive Phase II results for its lead candidate last year, Vaccinex will soon no longer be a publicly ...
Stock splits tend to create a lot of buzz in the market, especially when some of the most prominent companies announce a ...
Presiding over the upward trajectory of Eli Lilly over the last eight years is paying off nicely for CEO David Ricks. | ...
RiverPark Advisors, an investment advisory firm and sponsor of the RiverPark family of mutual funds, released its “RiverPark ...
US-based Eli Lilly's Kisunla drug and Japanese company Eisai's Leqembi (below), two breakthrough drugs for the diagnosis and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback